Sjögren’s Syndrome News

The FDA has granted breakthrough therapy designation to nipocalimab, a novel neonatal Fc receptor blocker, for the treatment of moderate to severe Sjögren’s disease, according to a press release from Johnson & Johnson.

Despite being one of the most prevalent autoimmune diseases in the United States, Sjögren’s disease remains shrouded behind significant misconceptions and knowledge gaps that can delay diagnosis and appropriate treatment.

Systemic treatment strategies lower the risk for new Sjögren’s disease activity when there are complications with marginal zone lymphoma, according to a study published in The Lancet Rheumatology.

SAN DIEGO — Determining which of several phenotypes a patient with Sjögren’s disease falls under can help inform their treatment strategy, according to data presented at the 2024 Congress of Clinical Rheumatology West.

New recommendations from the American College of Rheumatology and the American College of Chest Physicians strongly advise against glucocorticoids for interstitial lung disease in systemic sclerosis.

Despite being the second-most common rheumatic autoimmune disease in the United States, Sjögren’s syndrome remains under-recognized, with patients often waiting 3 years for a proper diagnosis, according to the Sjögren’s Foundation.

It has been at least 2 years since the first cohort of patients with lupus underwent chimeric antigen receptor T-cell treatment, and, at least so far, for every one of them, each new dawn represents another day spent in full remission.

Nightmares and hallucinations may occur at any stage of disease course in patients with systemic lupus erythematosus, according to recent findings.

Patients with Sjögren’s disease treated with nipocalimab, a novel neonatal Fc receptor blocker, demonstrate significant improvement vs. those who receive placebo at week 24, according to data presented at the EULAR 2024 Congress.